Company Intelligence Profile

Bugworks Research India Private Limited

Bugworks Research India develops new antibiotics for drug-resistant infections and cancer drug candidates, from Bangalore, as the Indian arm of Bugworks Research Inc.

CIN: U73100KA2014PTC073409ActiveRoC Bangalore

Last updated 15 October 2026

AI OverviewGenerated from public records

Bugworks Research India Private Limited is a Bangalore-based biopharma company that develops antibiotics for drug-resistant infections and oncology drug candidates. It was incorporated on 04 February 2014 and is the Indian subsidiary of Bugworks Research Inc. in the US. Its revenue for FY2024-25 was ₹25.18 Cr. It has no charges registered with the Registrar of Companies.

AI-generated summary from public filings and may contain errors. Verify against the detailed sections below.

See what AICA knows about Bugworks Research India

Deeper analysis, financial signals and peer comparisons.

Book a demo

Company Identity

Registered nameBUGWORKS RESEARCH INDIA PRIVATE LIMITED
CINU73100KA2014PTC073409
PANAAFCB8332C
StatusActive (Registrar of Companies compliance status
ListingUnlisted
Incorporated04 February 2014
ROCRoC Bangalore
Sector (NIC)Pharma & Life Sciences
Registered addressOffice No. 110-A, Evoma, No. 88, Borewell Road, Opposite Whitefield Post Office, Whitefield, Bangalore, Karnataka, India – 560066
Authorized capital₹1,00,000 (₹1 Lakh)
Paid-up capital₹1,00,000 (₹1 Lakh)

Source: MCA records via thecompanycheck.com, tofler.in

Business Overview

  • Bugworks Research India Private Limited is a clinical-stage biopharma company based in Bangalore.
  • It develops small-molecule antibiotics for multidrug-resistant infections and oncology candidates.
  • It is the Indian subsidiary of Bugworks Research Inc. (US) and was incorporated on 04 February 2014.

Source: bugworksresearch.com

Directors

  • Balasubramanian Venkataraman — Whole-Time Director, appointed 11 Sep 2014
  • Vasanthi Ramachandran — Director, appointed 26 May 2022
  • Shahul Hameed Peer Mohamed — Director, appointed 26 May 2022

Source: MCA records via thecompanycheck.com

GST Registration

GSTINStatePANStatus
29AAFCB8332C1ZTKarnatakaAAFCB8332CActive

Source: GST registry via knowyourgst.com

Financials

FY2024-25
  • Revenue ₹25.18 Cr

Source: thecompanycheck.com, indiankanoon.org

Funding

Series BUS$18M, announced Feb 2022
Series A₹62 crore, announced Aug 2018

Charges & Borrowings

  • No charges are registered with the Registrar of Companies.

Source: MCA records via thecompanycheck.com

Competitors

Jazz Pharmaceuticals
Dublin, Ireland
C4 Therapeutics
Cambridge, US
Erasca
San Diego, US
Nimbus Therapeutics
Cambridge, US
Mereo BioPharma
London, UK
Revolution Medicines
Redwood City, US

Source: thecompanycheck.com

Frequently Asked Questions

What does BUGWORKS RESEARCH INDIA PRIVATE LIMITED do?
It is a clinical-stage biopharma company that develops small-molecule antibiotics for multidrug-resistant infections and oncology candidates. It is the Indian subsidiary of Bugworks Research Inc. (US).
Who are the directors of BUGWORKS RESEARCH INDIA PRIVATE LIMITED?
The directors are Balasubramanian Venkataraman (Whole-Time Director, appointed 11 Sep 2014), Vasanthi Ramachandran and Shahul Hameed Peer Mohamed (both appointed 26 May 2022).
When was BUGWORKS RESEARCH INDIA PRIVATE LIMITED incorporated?
It was incorporated on 04 February 2014.
What is the CIN of BUGWORKS RESEARCH INDIA PRIVATE LIMITED?
The CIN is U73100KA2014PTC073409.
Where is BUGWORKS RESEARCH INDIA PRIVATE LIMITED registered?
It is registered with RoC Bangalore. The registered office is at Office No. 110-A, Evoma, No. 88, Borewell Road, Whitefield, Bangalore, Karnataka, 560066.

Recur Market

Which lenders fit a company like Bugworks Research India Private Limited?

Answer a few questions about your business and see which banks and NBFCs match, with indicative rates.

Similar Pharma & Life Sciences companies

More on Recur Club

Explore on Recur Club

More from Recur Club

Looking for business funding?

Recur Club is India's largest AI-native debt platform - working capital, term loans and structured debt from 150+ lending partners, without diluting equity.

Disclaimer: Company information shown on this page is compiled from public records and third-party sources. It may be incomplete, outdated, or contain inaccuracies, and is provided for general informational purposes only. Please verify details independently before relying on them.